Covid 19 Research using Clinical Trials (Home Page)
Report for D001008: Anxiety Disorders NIH
(Synonyms: Anxiety D, Anxiety Di, Anxiety Dis, Anxiety Diso, Anxiety Disor, Anxiety Disord, Anxiety Disorder, Anxiety Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (9)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug129 | Blood donation from convalescent donor Wiki | 0.50 |
| drug131 | Blood plasma Wiki | 0.50 |
| drug420 | Information-only intervention Wiki | 0.50 |
| drug128 | Blood and derivatives. Wiki | 0.50 |
| drug72 | Attention Bias Modification (ABM) Wiki | 0.50 |
| drug577 | Online Questionnaire Wiki | 0.50 |
| drug263 | Digital intervention Wiki | 0.50 |
| drug130 | Blood draw Wiki | 0.35 |
| drug771 | Standard of Care Wiki | 0.17 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013180 | Sprains and Strains NIH | 0.50 |
| D015352 | Dry Eye Syndromes NIH | 0.50 |
| D001248 | Asthenopia NIH | 0.50 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 4 clinical trials
Clinical Trials
1 Reducing Eye Strain and Anxiety Using a Digital Intervention During Online Learning Class Recess Among Children at Home: A Randomized Controlled Trial
The primary aim of the current study is to conduct a cluster-randomized control trial to evaluate the effectiveness of a novel digital intervention in reducing anxiety and digital eye strain compared to usual care among Chinese children during the period of home confinement.
NCT04309097 Anxiety Digital Eye Strain Dry Eye Syndromes Behavioral: Digital intervention Behavioral: Information-only intervention MeSH:Dry Eye Syndromes Asthenopia Sprains and Strains Anxiety Disorders
HPO:Keratoconjunctivitis sicca
Primary Outcomes
Description: Change in anxiety will be measured by the Spence Children's Anxiety Scale (SCAS) designed by Spence (1998). The SCAS (45-item) is self-report scale with a 4-point Likert type, consisting of 44 items and one open-ended question. Overall assessment is done by total score.
Measure: Change in anxiety Time: Baseline & at 2 weeks
Secondary Outcomes
Description: Syndromes of digital eye strain will be measured with the Computer Vision Syndrome Questionnaire (CVS‐Q) designed by Seguí et al (2015). The self-reported CVS-Q questionnaire (16-item) evaluates the frequency (never, occasionally or often/always) and the intensity (moderate or intense) of 16 symptoms: burning, itching, feeling of a foreign body, tearing, excessive blinking, eye redness, eye pain, heavy eyelids, dryness, blurred vision, double vision, difficulty focusing for near vision, increased sensitivity to light, colored halos around objects, feeling that sight is worsening, and headache. Overall assessment is done by total score.
Measure: Change in syndromes of digital eye strain Time: Baseline & at 2 weeks
Description: The PROMIS pediatric sleep disturbance questionnaire (4-item), designed by Forrest et al (2018), assesses self-reported experiences of sleep disturbance over the past 7 days. Raw score will be converted to T-Score.
Measure: Change in sleeping quality Time: Baseline & at 2 weeks
Description: Participants will be asked to indicate the average time in hours per day spent on each the following activities: reading, writing, computer/PAD use, smart phone, watching TV, and playing video games.
Measure: Changes in time (hour) spent on different near work activities Time: Baseline & at 2 weeks
2 Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany
Primary Outcomes
Description: Change in anxiety will be measured by the Spence Children's Anxiety Scale (SCAS) designed by Spence (1998). The SCAS (45-item) is self-report scale with a 4-point Likert type, consisting of 44 items and one open-ended question. Overall assessment is done by total score.
Measure: Change in anxiety Time: Baseline & at 2 weeksSecondary Outcomes
Description: Syndromes of digital eye strain will be measured with the Computer Vision Syndrome Questionnaire (CVS‐Q) designed by Seguí et al (2015). The self-reported CVS-Q questionnaire (16-item) evaluates the frequency (never, occasionally or often/always) and the intensity (moderate or intense) of 16 symptoms: burning, itching, feeling of a foreign body, tearing, excessive blinking, eye redness, eye pain, heavy eyelids, dryness, blurred vision, double vision, difficulty focusing for near vision, increased sensitivity to light, colored halos around objects, feeling that sight is worsening, and headache. Overall assessment is done by total score.
Measure: Change in syndromes of digital eye strain Time: Baseline & at 2 weeksDescription: The PROMIS pediatric sleep disturbance questionnaire (4-item), designed by Forrest et al (2018), assesses self-reported experiences of sleep disturbance over the past 7 days. Raw score will be converted to T-Score.
Measure: Change in sleeping quality Time: Baseline & at 2 weeksDescription: Participants will be asked to indicate the average time in hours per day spent on each the following activities: reading, writing, computer/PAD use, smart phone, watching TV, and playing video games.
Measure: Changes in time (hour) spent on different near work activities Time: Baseline & at 2 weeksThe study aims to systematically examine various aspects of the anxiety associated with the COVID-19 pandemic in Germany. The data collection is carried out online with longitudinal repeated measurements.
NCT04331106 Anxiety Related to the COVID-19 Pandemic Diagnostic Test: Online Questionnaire MeSH:Anxiety Disorders
Primary Outcomes
Description: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Characteristics of COVID-19-related anxiety Time: 1 dayDescription: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: COVID-19-related anxiety symptoms Time: 1 daySecondary Outcomes
Description: Self-efficacy and coping with the COVID-19 pandemic are measured with 13 self created items. Values ranging from 1 to 6; higher scores indicate a better outcome (except inverted items).
Measure: Self-efficacy and coping with COVID-19 Time: 1 day + every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: Personal consequences of the COVID-19 pandemic in the last three weeks are collected with five self-created items.
Measure: Consequences of COVID-19 in the last three weeks. Time: 1 day + every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: General illness attitudes are measured with 3 subscales (Worry about illness; Thanatophobia; Bodily preoccupations) of the German version of the Illness Attitude Scales (IAS) by Hiller & Rief (2004). 9 Items; values ranging from 1 to 5, higher scores indicate a worse outcome.
Measure: General Illness Attitude Time: 1 day + every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: Frequency, effects and formats of consumed media related to COVID-19 are measured with 5 self created items.
Measure: Media reporting Time: 1 day + every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: To screen for general anxiety and depressive symptoms the German version of the Patient Health Questionnaire-4 (PHQ-4) by Löwe (2015) is used. 4 items; values ranging from 0 to 3, higher scores indicate a worse outcome.
Measure: Ultra-brief screening scale for anxiety and depression Time: 1 day + every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.
Measure: Change in characteristics of COVID-19-related anxiety Time: Every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)Description: Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.
Measure: Change in COVID-19-related anxiety symptoms Time: Every 3 weeks as long as the COVID-19 pandemic lasts (maximum: 30 weeks from baseline on) and one year later (Follow-Up)3 The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic: TARUS
Background/Objectives: Psychological anxiety has been associated with alterations in eating patterns. The 2020 global coronavirus pandemic has created a situation characterized by increased anxiety. The present international survey was designed to examine associations between exposure to quarantine/isolation measures, anxiety levels and changes in dietary patterns. Methods: The present study utilizes a Google Survey platform to conduct an international survey querrying dietary patterns before vs. after the coronavirus pandemic; anxiety during the pandemic; and demographic characteristics. The nutrition portion of the survey is based on the Mediterranean Diet Score while the anxiety estimate is based on the GAD-7. The survey is available in English, Hebrew, Spanish, Italian, French, Arabic and Russian. It has been distributed via social media. Anticipated Results: We believe that changes in dietary habits will be identified and that these will be associated with anxiety levels. Additionally, we believe that by-country differences will be identified. Discussion: The Google Survey format distributed by social media provides an almost immediate means of distributing the survey globally. The survey can only be completed if the respondent first indicates his/her informed consent. The convenience sample limits generalizability to individuals who volunteer to complete online surveys; however, we anticipate a large response which may mitigate this limitation.
NCT04353934 Dietary Habits Anxiety MeSH:Coronavirus Infections Anxiety Disorders
Primary Outcomes
Description: The Mediterranean Diet Score (MedDiet Score) will be calculated and correlated to the Anxiety Score (GAD-7)
Measure: The association between Mediterranean Diet Score and Anxiety Score Time: through study completion, average six monthsDescription: Mediterranean Diet Score (MedDiet) will be calculated
Measure: The degree to which current dietary intake is consisten with the Mediterranean Diet Time: through study completion, average six monthsSecondary Outcomes
Description: By-country comparisons of the association between Mediterranean Diet (MedDiet) score and Anxiety (GAD-7)
Measure: By-country comparisons of the association between Mediterranean Diet (MedDiet) score and Anxiety Time: through study completion, average six months4 Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial
The outbreak of the 2019 Coronavirus (COVID-19) pandemic is a major stressor leading to increased levels of anxiety, and specifically, an excessive fear of being infected and affected by the disease among major parts of the population. At the same time, the access to mental health services is limited due to the lockdown policy applied in many countries worldwide, warranting the development of home-delivered interventions aimed at reducing stress and anxiety symptoms. Attention Bias modification (ABM) has been found to be an efficacious computerized intervention to reduce anxiety symptoms. In this open pilot trial, participants reporting on elevated levels of health anxiety concerning the COVID-19 epidemic will receive one session of ABM over 5 consecutive days (5 sessions total). Symptoms of health anxiety, state anxiety, generalized anxiety, and depression will be measured at baseline and post-treatment.
NCT04365972 Anxiety Behavioral: Attention Bias Modification (ABM) MeSH:Anxiety Disorders
Primary Outcomes
Description: The COVID-19 anxiety inventory is a self-report questionnaire screening for concerns and fears regarding COVID-19 contagion. The Inventory consists of 7 items. Scores can range from 5 to 35, with higher scores denoting higher symptom severity.
Measure: Change from baseline of the total score of a novel COVID-19 anxiety inventory Time: up to 2 days pre-treatment and 1-2 days post-treatmentSecondary Outcomes
Description: The Health Anxiety Inventory (HAI) is a validated self-report measure assessing health anxiety. Average score can range from 0 to 3, with higher scores denoting higher symptom severity
Measure: Change from baseline of the average score of the Health Anxiety Inventory Time: up to 2 days pre-treatment and 1-2 days post-treatmentDescription: The State Anxiety Inventory is a validated self-report measure for state anxiety. Average score can range from 1 to 4, with higher scores denoting higher levels of state anxiety.
Measure: Change from baseline of the average score of the State Anxiety Inventory Time: up to 2 days pre-treatment and 1-2 days post-treatmentDescription: The PHQ-9 is a 9-item self-report scale for depression symptoms. Scores can range from 0 to 27, with higher scores reflecting more symptoms of depression.
Measure: Change from Baseline of the total score of the PHQ-9 Time: up to 2 days pre-treatment and 1-2 days post-treatmentDescription: The GAD-7 is a 7-item self-report scale for generalized anxiety symptoms. Scores can range from 0 to 21, with higher scores reflecting more symptoms of generalized anxiety.
Measure: Change from Baseline of the total score of the GAD-7 Time: up to 2 days pre-treatment and 1-2 days post-treatment